Efficacy Of Topical Losartan In The Treatment Of Corneal Scarring: A Clinical Study

Corneal scarring resulting from ocular surgery, trauma, or chemical injury represents a significant clinical challenge due to the limited availability of effective treatments. This study aimed to evaluate the therapeutic potential of topical Losartan in the management of moderate-to-severe corneal scarring, particularly in patients who had not responded to conventional therapeutic approaches.

Prospective clinical trial conducted at the Vision Health Research Center of Semnan University of Medical Sciences.

Ten patients with corneal scarring of various etiologies were enrolled in this study. A topical losartan solution (0.8 mg/mL) was administered every four hours daily. The extent and depth of corneal scarring and opacity were evaluated using slit-lamp bio-microscopy and Optical Coherence Tomography at baseline and after 3-6-9-12 months of treatment.

Following treatment, the mean depth of corneal scars decreased significantly from 208.1 ± 103.73 µm to 152.9 ± 71.517 µm. Moreover, uncorrected visual acuity (UCVA) improved from 3/10 to 5/10, while best-corrected visual acuity (BCVA) improved from 5/10 to 7/10. No significant changes in intraocular pressure (IOP) were observed. Additionally, no adverse events or serious complications were detected based on evaluation with Specular Microscopy.

These findings suggest that topical losartan may represent a safe and effective therapeutic approach for the management of corneal scarring, with the potential to improve visual outcomes. Further studies with larger patient cohorts are required to confirm its clinical efficacy and to optimize treatment protocols.